{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Opioid+Abuse+Nondependent", "query": { "condition": "Opioid Abuse Nondependent" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 6, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T00:22:17.116Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06453265", "title": "A Study to Assess the Abuse Potential of Intranasal Cebranopadol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Abuse, Drug" ], "interventions": [ { "name": "Cebranopadol- 600 ug", "type": "DRUG" }, { "name": "Cebranopadol- 800ug", "type": "DRUG" }, { "name": "Cebranopadol- 1000ug", "type": "DRUG" }, { "name": "Treatment A:", "type": "DRUG" }, { "name": "Treatment B", "type": "DRUG" }, { "name": "Treatment C", "type": "DRUG" }, { "name": "Qualification", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tris Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2024-06-28", "completion_date": "2024-11-06", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-07-24T00:22:17.116Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06453265" }, { "nct_id": "NCT01596673", "title": "A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Abuse" ], "interventions": [ { "name": "45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cephalon", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 100, "start_date": "2012-03", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-11-21", "last_synced_at": "2026-07-24T00:22:17.116Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01596673" }, { "nct_id": "NCT06247488", "title": "Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Abuse Potential" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Oxycodone 20 mg", "type": "DRUG" }, { "name": "GE-IR 200 mg", "type": "DRUG" }, { "name": "GE-IR 450 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arbor Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 110, "start_date": "2022-01-31", "completion_date": "2023-04-25", "has_results": true, "last_update_posted_date": "2024-08-12", "last_synced_at": "2026-07-24T00:22:17.116Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06247488" }, { "nct_id": "NCT05256108", "title": "Assessment of Abuse Potential of Cebranopadol in Humans", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Abuse Potential" ], "interventions": [ { "name": "Oxycodone 40 mg", "type": "DRUG" }, { "name": "Tramadol 600 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cebranopadol 600 µg", "type": "DRUG" }, { "name": "Cebranopadol 1000 µg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tris Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 38, "start_date": "2022-03-28", "completion_date": "2022-07-12", "has_results": false, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-07-24T00:22:17.116Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05256108" }, { "nct_id": "NCT01380093", "title": "Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nondependent Opioid Abuse, Episodic" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "MS Contin (morphine sulfate, controlled release)", "type": "DRUG" }, { "name": "EMBEDA (morphine sulfate / naltrexone hydrochloride)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 80, "start_date": "2011-02", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2012-05-31", "last_synced_at": "2026-07-24T00:22:17.116Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01380093" }, { "nct_id": "NCT03475862", "title": "Nasal Human Abuse Potential of PTI-821", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opioid Abuse Nondependent" ], "interventions": [ { "name": "PTI-821 capsule Manipulated", "type": "DRUG" }, { "name": "PTI-821 Non-manipulated", "type": "DRUG" }, { "name": "OxyContin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Oxycodone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pain Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 38, "start_date": "2017-05-15", "completion_date": "2017-12-15", "has_results": false, "last_update_posted_date": "2018-03-23", "last_synced_at": "2026-07-24T00:22:17.116Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03475862" } ] }